Trial Profile
A Randomized, Double-Blind, Placebo-Controlled Trial Of Neratinib (HKI-272) After Trastuzumab In Women With Early-Stage HER-2/Neu Overexpressed/Amplified Breast Cancer
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 14 Jul 2023
Price :
$35
*
At a glance
- Drugs Neratinib (Primary)
- Indications Adenocarcinoma; Ductal carcinoma; Early breast cancer; HER2 positive breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms ExteNET
- Sponsors Pfizer; Puma Biotechnology; Wyeth
- 10 Feb 2023 Results of final analysis of overall survival in patients with neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer , published in the European Journal of Cancer
- 21 Sep 2021 Amendment 3: ruled out patients with stage I/ node negative disease, and those with pCR after neoadjuvant therapy, in order to enrich population with patients at higher risk of recurrence.
- 08 Jun 2021 Results of a a systematic analysis of tolerability in CONTROL and ExteNET studies presented at the 57th Annual Meeting of the American Society of Clinical Oncology